Cytoskeletal active agents for glaucoma therapy
AssigneesWisconsin Alumni Research Foundation, Yeda Research and Development Co. Ltd.
InventorsPaul L. Kaufman, Benjamin Geiger
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of glaucoma are provided by the present invention. The compounds described cause a perturbation of the actin cytoskeleton in the trabecular meshwork or the modulation of its interactions with the underlying membrane. Perturbation of the cytoskeleton and the associated adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
Claims19
A method of enhancing aqueous humor outflow in the eye of a subject, comprising:
- a) providing a subject and an effective amount of at least one non-corneotoxic ophthalmic preparation that affects actin filament integrity in the eye of said subject;
- and
- b) administering to said subject, said preparation, whereby the aqueous humor outflow of said subject is enhanced.
A method of enhancing aqueous humor outflow in the eye, comprising:
- a) providing a subject having glaucoma, and an ophthalmic preparation comprising an effective amount of at least one macrolide or a pharmaceutically acceptable salt thereof;
- and
- b) administering said ophthalmic preparation to said subject thereby enhancing aqueous humor outflow in the eye of said subject.
A method of preventing the progression of glaucoma, comprising the steps of:
- a) providing a subject having glaucoma and a non-comeotoxic ophthalmic preparation that affects actin filament integrity in the eye;
- and
- b) administering said non-comeotoxic ophthalmic preparation to said subject under conditions such that the progression of said glaucoma is prevented.
Dependencies are inferred from the claim text.